{
    "nct_id": "NCT05352828",
    "official_title": "Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)",
    "inclusion_criteria": "1. Signed ICF\n2. Male or female patients who are 12 years of age and above\n3. Relapsed or refractory CD30+ cHL following failure of a standard frontline chemotherapy\n4. At least 1 lesion, which must be fluordeoxyglucose positron emission tomography (FDG-PET) avid and measurable by PET-CT scan\n5. Adequate laboratory parameters including hematologic, renal, hepatic, and coagulation function\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, or equivalent either Karnofsky performance status (for patients â‰¥ 16 years of age) or Lansky performance status (for patients < 16 years of age)\n7. Anticipated life expectancy > 12 weeks\n8. No active infections including COVID 19 at Screening\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "1. Evidence of lymphomatous involvement of the central nervous system (CNS)\n2. Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement\n3. Symptomatic cardiovascular disease: Class III or IV according to the New York Heart Association (NYHA) Functional Classification\n4. Active uncontrolled bleeding or a known bleeding diathesis\n5. Inadequate pulmonary function defined as oxygen saturation by pulse oximetry < 90% on room air\n6. Echocardiogram (ECHO) or Multi-gated Acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) < 45%\n7. Prior receipt of salvage therapy, for relapsed or refractory cHL, including allogeneic or ASCT\n8. Prior receipt of investigational CD30.CAR-T cells\n9. Receiving any investigational agents or any tumor vaccines\n10. Receiving any live/attenuated vaccines\n11. Ongoing treatment with immunosuppressive drugs or chronic systemic corticosteroids\n12. Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments\n13. Previous history of known or suspected autoimmune disease within the past 5 years\n14. Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity\n15. Evidence of human immunodeficiency virus (HIV) infection\n16. Evidence of active viral infection with hepatitis B virus (HBV)\n17. Evidence of active viral infection with hepatitis C virus (HCV)\n18. Active second malignancy or history of another malignancy within the last 3 years\n19. History of hypersensitivity reactions to murine protein-containing products or other product excipients\n20. Any allergic or adverse reaction to nivolumab, fludarabine, or bendamustine that precludes treatment with these agents\n21. History of a significant irAE from prior immune checkpoint inhibitor therapy",
    "miscellaneous_criteria": ""
}